Quick Answer
C4 Therapeutics, Inc. reported Total Assets of $359.08 million for the year ending 2025.
- C4 Therapeutics, Inc. showed an increase of +2.7% in Total Assets from 2024 to 2025.
- This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $229.13 million | Q1 2021: $374.01 million | Q2 2021: $528.42 million | Q3 2021: $507.91 million | Q1 2022: $515.49 million | Q2 2022: $492.48 million | Q3 2022: $461.44 million | Q1 2023: $396.04 million | Q2 2023: $375.01 million | Q3 2023: $333.01 million | Q1 2024: $398.37 million | Q2 2024: $381.09 million | Q3 2024: $376.06 million | Q1 2025: $319.52 million | Q2 2025: $296.53 million | Q3 2025: $265.49 million.
- Over the full 7 years of available data (2019 to 2025), C4 Therapeutics, Inc.'s Total Assets has grown by 203.6%.
- Historical annual values: Fiscal year 2025: $359.08 million | Fiscal year 2024: $349.60 million | Fiscal year 2023: $376.45 million | Fiscal year 2022: $430.84 million | Fiscal year 2021: $506.77 million | Fiscal year 2020: $400.14 million | Fiscal year 2019: $118.26 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: